Fundz

Thermo Fisher Scientific

Waltham, Massachusetts, United States · Biotechnology, Health Care, research

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through

Key facts

Headquarters
Waltham, Massachusetts, United States
Employees
125,000
Industries
Biotechnology, Health Care, research
Status
Public (TMO)
Website
https://www.thermofisher.com
LinkedIn
Company page

Recent activity at Thermo Fisher Scientific

  • : Michael D. Shafer to Retire from Thermo Fisher Scientific
  • : Thermo Fisher Scientific launches the Multiskan Ease absorbance microplate reader aimed at enhancing routine laboratory applications.
  • : Thermo Fisher acquires Clario for $8.875 billion
  • : SEC 8-K (5.02): On October 27, 2026, Thermo Fisher Scientific Inc. announced that Michael D. Shafer, the Executive Vice President of the Company, will retire effective December 31, 2026. This announcement indicates a significant change in the management structure of the Company, highlighting the upcoming departure of a key executive. The timing of this announcement and the scheduled retirement date suggest that the Company is planning for a transition in leadership, which may impact strategic decisions moving forward. No financial implications were mentioned in the filing.
  • : SEC 8-K (8.01): On March 24, 2026, Thermo Fisher Scientific Inc. announced the completion of its acquisition of Clario Holdings, Inc. This strategic acquisition enhances Thermo Fisher's capabilities in the life sciences sector and expands its market offerings. The press release detailing the acquisition was issued on the same date and provides further insights into the financial implications and expected synergies from the deal. The completion of the acquisition significantly strengthens Thermo Fisher's position in the industry.
  • : SEC 8-K (1.01): On February 12, 2026, Thermo Fisher Scientific Inc. entered into a material definitive agreement by issuing $1,000,000,000 of 4.215% Senior Notes due 2031, $750,000,000 of 4.550% Senior Notes due 2033, $1,300,000,000 of 4.902% Senior Notes due 2036, and $750,000,000 of 5.546% Senior Notes due 2046 in a public offering according to a previously filed registration statement. These notes will mature at various future dates between 2031 and 2046, and interest will be paid semi-annually starting from August 12, 2026, for the 2031, 2036, and 2046 Notes and from June 15, 2026, for the 2033 Notes. The agreement allows for redemption of the notes prior to their respective Par Call Dates under specified terms. This significant transaction raises funds for Thermo Fisher's ongoing business operations and strategic initiatives.
  • : SEC 8-K (5.02):
  • : SEC 8-K (1.01): On December 1, 2025, Thermo Fisher Scientific (Finance I) B.V., a wholly-owned finance subsidiary of Thermo Fisher Scientific Inc., entered into a material definitive agreement by issuing €1,000,000,000 in Floating Rate Senior Notes due 2027 and €1,100,000,000 in 3.628% Senior Notes due 2035 as part of a public offering. The company fully guaranteed these notes on a senior unsecured basis. This issuance is expected to provide significant capital for future operations and projects. Interest on the notes is scheduled to begin in March and December 2026, respectively, with terms allowing for potential redemption under specified conditions starting in 2035.
  • : SEC 8-K (8.01): On October 29, 2025, Thermo Fisher Scientific Inc. announced the execution of a definitive agreement to acquire Clario Holdings, Inc. for approximately $8.875 billion in cash at closing, along with an additional $125 million in deferred consideration and up to $400 million in contingent consideration post-closing. This acquisition is expected to be completed by mid-2026, subject to customary closing conditions and regulatory approvals. The strategic implication of this acquisition indicates Thermo Fisher's intent to enhance its service offerings and market position in the scientific sector, with the potential to generate significant synergies and operating efficiencies once integrated.
  • : SEC 8-K (2.02): On October 22, 2025, Thermo Fisher Scientific Inc. entered into a material definitive agreement involving a series of senior notes offerings. The agreements cover several tranches of notes with various due dates ranging from 2026 to 2049, including 3.200% Notes due 2026, 1.400% Notes due 2026, 1.450% Notes due 2027, and others, totaling significant financial commitments. The notes are to be traded on the New York Stock Exchange under the ticker symbols corresponding to each series. This move is strategically aimed at raising capital for future investments and refinancing existing debts, reflecting Thermo Fisher's ongoing growth and operational strategy.

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

Leadership

  • Dominic Meusch, Global Director Segment Strategy
  • Michael D. Shafer, Executive Vice President
  • Efthymios Vogiatzis, Product Line Owner
  • Abdel Hady Mansour, Chief Technology Officer
  • Aditya Joshi, Chief Strategy Officer
  • Rupali Lach, Vice President Of Commercial Operations
  • Sumit Pathare, Director
  • Marc Casper, Chief Executive Officer

Verified email and direct lines for Thermo Fisher Scientific’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.

Employee benefit plans

Thermo Fisher Scientific files 8 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

Thermo Fisher Scientific in the news

Companies similar to Thermo Fisher Scientific

About Thermo Fisher Scientific: questions and answers

What does Thermo Fisher Scientific do?

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through

Where is Thermo Fisher Scientific headquartered?

Thermo Fisher Scientific is headquartered in Waltham, Massachusetts, United States.

How many employees does Thermo Fisher Scientific have?

Thermo Fisher Scientific has about 125,000 employees.

Who leads Thermo Fisher Scientific?

Michael D. Shafer is an Executive Vice President at Thermo Fisher Scientific.

What is the latest news on Thermo Fisher Scientific?

On Oct 30, 2026, Michael D. Shafer to Retire from Thermo Fisher Scientific

Is Thermo Fisher Scientific a public company?

Yes. Thermo Fisher Scientific is publicly traded under the ticker TMO.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Thermo Fisher Scientific across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.